Cancer Genetics Inc (CGIX) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $6. Rodman & Renshaw advised their investors in a research report released on Sep 26, 2016.
On the company’s financial health, Cancer Genetics Inc reported $-0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.33. The company had revenue of $7.00 million for the quarter, compared to analysts expectations of $6.50 million. The company’s revenue was up 67.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.
Cancer Genetics Inc closed down -0.04 points or -2.15% at $1.82 with 49,851 shares getting traded on Thursday. Post opening the session at $1.86, the shares hit an intraday low of $1.8 and an intraday high of $1.8999 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Mar 18, 2016, Howard Mcleod (director) purchased 1,000 shares at $2.71 per share price. According to the SEC, on Mar 17, 2016, Panna Sharma (CEO) purchased 1,500 shares at $2.59 per share price. On Mar 17, 2016, Michael J. Welsh (director) purchased 40 shares at $2.42 per share price, according to the Form-4 filing with the securities and exchange commission.
Cancer Genetics Inc. is an oncology diagnostics company focused on developing commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors including cancer centers and hospitals biotechnology and biopharmaceutical companies and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological urogenital and HPV-associated cancers in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.